IFIT1 inhibitors represent a heterogeneous class of chemicals with distinct mechanisms of action on the intricate signaling pathways that regulate IFIT1 expression and function. Ruxolitinib, a JAK inhibitor, directly targets the JAK/STAT pathway and represents a specific tool for studying IFIT1-related cellular processes. Fludarabine indirectly inhibits IFIT1 by modulating the adenosine signaling pathway, disrupting the intricate network of signaling pathways that converge on IFIT1 expression. Sunitinib, a receptor tyrosine kinase inhibitor, indirectly influences IFIT1 by targeting the VEGF pathway, offering insights into the crosstalk between angiogenesis and IFIT1-related cellular processes. Niclosamide indirectly inhibits IFIT1 by modulating the Wnt/β-catenin signaling pathway, providing an indirect mechanism to inhibit IFIT1-mediated responses by disrupting the intricate network of signaling pathways that converge on IFIT1 expression.
Dasatinib, Imatinib and Ibrutinib indirectly affect IFIT1 by targeting the Src, ABL and BTK signaling pathways, respectively, offering insights into the role of these kinases in IFIT1-related cellular processes. SB203580, a p38 MAPK inhibitor, indirectly inhibits IFIT1 by disrupting the p38 MAPK signaling pathway, shedding light on the mechanisms of regulation of IFIT1 expression. Trametinib, a MEK inhibitor that acts on the MAPK pathway, indirectly affects IFIT1, providing insights into the intricate network of signaling pathways that regulate IFIT1. Rapamycin indirectly inhibits IFIT1 by targeting the mTOR signaling pathway, disrupting the regulatory network of IFIT1 expression. SB202190, a selective inhibitor of p38 MAPK, and MK-2206, an inhibitor of Akt, indirectly inhibit IFIT1 by targeting the p38 MAPK and PI3K/Akt signaling pathways, respectively, providing valuable tools to unravel the complexities of IFIT1-related cellular processes. These IFIT1 inhibitors offer a comprehensive toolkit for researchers wishing to analyze the regulatory networks that regulate IFIT1 expression and function. The diverse mechanisms of action of these chemicals provide unique insight into the intricate signaling pathways that converge on IFIT1, contributing to the understanding of molecular events regulated by IFIT1 in various cellular contexts.
Items 11 to 12 of 12 total
Schermo:
Nome del prodotto | CAS # | Codice del prodotto | Quantità | Prezzo | CITAZIONI | Valutazione |
---|---|---|---|---|---|---|
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB202190 è un inibitore selettivo di p38 MAPK che influisce indirettamente su IFIT1, colpendo la via di segnalazione p38 MAPK. Inibendo p38 MAPK, SB202190 interrompe gli eventi a valle, compresa la regolazione di IFIT1. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
MK-2206, un inibitore di Akt, influisce indirettamente su IFIT1, puntando la via di segnalazione PI3K/Akt. Inibendo Akt, MK-2206 interrompe gli eventi a valle, compresa la regolazione di IFIT1. La via PI3K/Akt è stata implicata nel controllo dell'espressione di IFIT1 e l'impatto di MK-2206 sulla segnalazione PI3K/Akt fornisce un meccanismo indiretto per inibire le risposte mediate da IFIT1, interrompendo l'intricata rete di vie di segnalazione che convergono sull'espressione di IFIT1. |